FibroGen Reports Fourth Quarter and Full Year 2019 Financial Results
02 mars 2020 16h01 HE
|
FibroGen, Inc
Roxadustat NDA submission accepted with PDUFA date of December 20, 2020Pamrevlumab pivotal trials for treatment of idiopathic pulmonary fibrosis (IPF) and locally advanced unresectable pancreatic...
FibroGen Announces Roxadustat Inclusion in China’s National Reimbursement Drug List
02 déc. 2019 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, Dec. 02, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported roxadustat has been included on the updated National Reimbursement Drug List (NRDL) released by China’s...
FibroGen To Report Third Quarter 2019 Financial Results on Monday, November 11, 2019
04 nov. 2019 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, Nov. 04, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced that financial results for the third quarter 2019 will be released after market on Monday, November...
CORRECTION - FibroGen to Report Second Quarter 2019 Financial Results on Thursday, August 8, 2019
01 août 2019 20h39 HE
|
FibroGen, Inc
SAN FRANCISCO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by FibroGen, Inc (NASDAQ: FGEN) we are advised by the company the “Live (U.S./Canada)”...
FibroGen to Report Second Quarter 2019 Financial Results on Thursday, August 8, 2019
01 août 2019 19h24 HE
|
FibroGen, Inc
SAN FRANCISCO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced that it will report second quarter 2019 financial results on Thursday, August 8, 2019 after market...
FibroGen to Report Third Quarter 2018 Financial Results on Thursday, November 8, 2018
02 nov. 2018 17h02 HE
|
FibroGen, Inc
Conference Call and Audio Webcast Scheduled for 5:00 p.m. ET (2:00 p.m. PT) SAN FRANCISCO, Nov. 02, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a biopharmaceutical company, today...
FibroGen Reports Second Quarter 2018 Financial Results
07 août 2018 16h02 HE
|
FibroGen, Inc
Roxadustat U.S. Phase 3 Topline Clinical Data Readout on Track for Fourth Quarter of 2018 Feedback from FDA on Pamrevlumab Pivotal Programs in IPF and in Locally Advanced Unresectable Pancreatic...
FibroGen to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018
01 août 2018 17h21 HE
|
FibroGen, Inc
SAN FRANCISCO, Aug. 01, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a biopharmaceutical company, today announced that it will report second quarter 2018 financial results on Tuesday,...
FibroGen Reports Third Quarter 2017 Financial Results
08 nov. 2017 16h02 HE
|
FibroGen, Inc
Roxadustat NDA Filing Accepted for CFDA Review; Positive Pamrevlumab Phase 2 IPF Results ReportedConference Call and Webcast to be Held Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time ...
FibroGen to Report Third Quarter Financial Results on Wednesday, November 8, 2017
30 oct. 2017 20h00 HE
|
FibroGen, Inc
SAN FRANCISCO, Oct. 30, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that it will report financial results for the third quarter...